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Introduction
There has been an increasing interest in the regula-
tion of colonic microfl ora in order to improve the host’s 
health. This has been achieved traditionally by dietary in-
clusion of live microbes as food supplements known as 
probiotics. An alternative approach involves the con-
sumption of food ingredients known as prebiotics. Prebi-
otics may provide advantages to probiotic bacteria in the 
gastrointestinal tract and additionally exert direct eﬀ ects 
on the microfl ora in the large intestine (1).
Galactooligosaccharides (GOS) that consist of 3–10 
molecules of galactose and glucose are known to facilitate 
the growth of desirable intestinal microfl ora and are con-
sidered as potent non-digestible prebiotics (2). Commer-
cial GOS that contain complex mixtures of oligosaccha-
rides with diﬀ erent glycosidic linkages and degrees of 
polymerization are usually synthesized by enzymatic 
transgalactosylation of lactose by β-galactosidases from 
various sources such as yeast, fungi or bacteria (3,4). In 
addition, these kinds of products can also contain trans-
galactosylated oligosaccharides, unreacted lactose, glu-
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benefi cial eﬀ ects on intestinal microbiota and gut barrier function. In this study, high-puri-
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of Bifi dobacterium bifi dum and B. longum in the gut increased most rapidly up to 12 h, and 
thereaft er the increase was slow. Therefore, 1 % HP-GOS was found to be acceptable for 
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and bifi dobacteria during the study, and the group administered HP-GOS during the 2nd 
(days 13–15) and 4th (days 28–30) period of the study had signifi cantly (p<0.05) higher 
numbers of bifi dobacteria in faeces than groups receiving a single dose of bifi dobacteria. 
HP-GOS aﬀ ected the expression of genes encoding glucagon-like peptide-1 (GLP-1) and 
peptide YY (PYY). There was a signifi cant upregulation of GLP-1 and PYY mRNA with 
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cose and galactose, which do not have prebiotic proper-
ties but only the caloric value (5).
The most eﬃ  cient process to produce high-purity 
GOS (HP-GOS) is yeast fermentation of sugars such as 
glucose, galactose and lactose (6). Cardelle-Cobas et al. (7) 
fi rst reported the production of non-monosaccharides and 
HP-GOS by repeated batch fermentation with immobi-
lized yeast cells. A GOS syrup of an increased purity was 
produced by immobilized β-galactosidase from Penicilli-
um expansum F3 and subjected to fermentation by Saccha-
romyces cerevisiae L1 and Kluyveromyces lactis L3 (8). This 
was a feasible industrial process to produce high-purity 
GOS.
Among numerous non-digestible carbohydrate-based 
prebiotics, convincing scientifi c evidence for suitability 
for use as prebiotics exists only for inulin/oligofructose 
and GOS (9). Studies of the prebiotic eﬀ ects of GOS and 
FOS in humans have shown that a daily dose of 4–20 g 
signifi cantly increases the population of lactobacilli and 
bifi dobacteria in the gut (10). Other eﬀ ects, such as hypo-
cholesterolemic eﬀ ects, prevention of colon cancer, and 
enhancement of calcium absorption have been described 
(11,12). Numerous studies have reported data on the ef-
fects of non-digestible oligosaccharides (NDOs) and di-
etary fi bre content on serum cholesterol and lipid levels; 
however, only a limited number of reports indicate posi-
tive eﬀ ects of GOS (13) or inulin (14) on serum cholesterol 
metabolism in humans. Yamashita et al. (15) suggested 
fi rst that dietary inclusion of fructooligosaccharides dem-
onstrated hypocholesterolemic eﬀ ect in diabetic subjects.
In this paper, the ability of HP-GOS to support the in 
vitro growth of selected strains of probiotic bacteria, 
namely Lactobacillus acidophilus, Lactobacillus casei, Bifi do-
bacterium bifi dum and Bifi dobacterium longum, is investigat-
ed. In addition, it was determined whether oral adminis-
tration of HP-GOS aﬀ ected the growth of bifi dobacteria, 
as well as serum cholesterol and nitrogen levels and the ex-
pression of gene encoding glucagon-like peptide-1 (GLP- 
-1) and tyrosine-tyrosine peptide (PYY), which act as sig-
nifi cant modulators of appetite via their peripheral eﬀ ects 
(on the vagus nerve) and/or by infl uencing directly the ar-
cuate nucleus in the rat.
Materials and Methods
Materials
HP-GOS, containing 75.18 % of galactooligosaccha-
rides (by mass), were obtained from Neo Cremar Co. Ltd, 
Seoul, Republic of Korea. Commercial GOS, Y-GOS (52.52 
% GOS, by mass; Yakult Honsha, Tokyo, Japan), C-GOS 
(56.25 % GOS, by mass; Doosan Corn Products Korea, 
Seoul, Republic of Korea), and Q-GOS (41.77 % GOS, by 
mass; Samyang Genex, Inchon, Republic of Korea) were 
purchased from a local market in Seoul, Republic of Ko-
rea. A commercial β-galactosidase from Bacillus circulans 
was obtained from Bision Corporation (Seongnam, Re-
public of Korea).
Production of GOS
Batch reactions were performed by incubating β-ga-
lactosidase with a 40–45 °Brix lactose solution in a 100-li-
tre incubator shaker at 150 rpm. Lactose (25 kg) was dis-
solved in distilled water (60 L), and 0.08 % (by mass) 
β-galactosidase from Bacillus circulans was added to syn-
thesize GOS at 55 °C and pH=6.0 for 24 h. All reactions 
were terminated by incubation at 100 °C for 10 min and 
the sugar profi le was analyzed by high-performance liq-
uid chromatography. To increase the GOS content, 100 
mL of 20 % (by mass) GOS syrup produced by enzymatic 
hydrolysis with β-galactosidase were fermented by 8 % 
(by mass) of fresh yeast (Saccharomyces cerevisiae L1). The 
fermentation process was carried out in a shaking incuba-
tor at 100 rpm and 30 °C for 24 h. Aft er each fermentation 
cycle, cells were transferred to 20 % (by mass) GOS syrup, 
which was then fi ltered and treated with active carbon for 
decolourization. Ion exchange chro matography using Am-
berlite® CG-120-II column (Sigma-Aldrich, Buchs, Swit-
zerland) was utilized for further purifi cation. The pooled 
fractions were evaporated to 45 °Brix and dried with a 
spray dryer. Lactose and HP-GOS were determined by an 
HPLC system with Waters® 2414 refractive index detector 
(RID) (Waters Corporation, Milford, MA, USA) equipped 
with YMC-Pack Polyamine II column (4 mm×250 mm; 
YMC Co. Ltd, Kyoto, Japan), column heater (30 °C), and 
RID detector. Acetonitrile (64 %) was used as mobile 
phase.
Bacterial strains and growth conditions
Lactobacillus acidophilus DDS-1, L. casei KCTC 12452, 
Bifi dobacterium bifi dum KCTC 3357 and B. longum SJ 32 
were obtained from the culture collection from the Korea 
Research Institute of Bioscience and Biotechnology, Dae-
jeon, Republic of Korea. The cultures were grown at 37 °C 
in modifi ed peptone yeast extract fructose (PYF) medium 
without carbon source consisting of (in %, by mass): yeast 
extract 1, peptone 0.5, l-cysteine HCl 0.5 and salt solution 
4 (containing (in %, by mass): CaCl2 0.02, MgSO4 0.02, 
K2HPO4 0.1, KH2PO4 0.1, NaCl 0.2 and Na2HPO3 1.0) (16). 
The medium was supplemented with 0.5, 1, 2 or 4 % (by 
mass) GOS. Microplates were incubated anaerobically at 
37 °C in a GasPak™ container (BD (Becton, Dickinson and 
Company), Franklin Lakes, NJ, USA). The absorbance at 
600 nm (A600 nm) was recorded by the microplate reader at 
0, 24 and 48 h. At 24 h, aft er the measurement of A600 nm, 
the plates were placed in the incubator to restore anaero-
bic conditions.
Animals and diet
The experimental protocol was reviewed and ap-
proved by Institutional Animal Care and Use Committ ee 
of Korea University. Four-week-old male Sprague Daw-
ley® (SD) rats were purchased from Daehan Biolink Co. 
Ltd. (Cheongju, Republic of Korea). The animals were 
kept in a room at 24 °C and constant atmosphere with 60 
% humidity and a 12-hour light/dark cycle. Rats were fed 
an AIN-93G diet based on the main ingredients of corn 
starch (40 %) and casein (20 %) (17). Aft er an adaptation 
period, the rats were randomly divided into four groups 
(N=8): the control group (oral administration of saline), 
the HP-GOS group (oral administration of HP-GOS), the 
HP-GOS+BB group (oral administration of HP-GOS and 
bifi dobacteria), and the BB group (oral administration of 
bifi dobacteria). The groups were orally administrated 
HP-GOS (1.5 mL of the solution of 1 g of HP-GOS and/or 
109 CFU bifi dobacteria) daily for 5 weeks.
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Fresh faecal samples were collected weekly (equal 
mass from four rats per pool) in sterile fl asks, and kept at 
–80 °C for microbiological analysis. To count the total 
number of bifi dobacteria, 3 g of faecal sample were dilut-
ed in 25 mL of dilution solution and an aliquot of 0.2 mL 
was spread on Petri dishes using BL agar. Colonies were 
incubated anaerobically during 2–3 days at 37 °C under 
anaerobic conditions and results were measured as the 
log CFU per gram of faecal sample.
At the end of the study, the rats were euthanized 
using CO2 asphyxiation and the liver, kidney and spleen 
were removed and weighed immediately. The body mass 
of each rat was measured every week for 5 weeks and the 
mass of each organ was expressed as 100 g of body mass.
Blood analysis
Blood samples were collected into non-heparinized 
serum separator tubes. Serum triglycerides (TGs), total 
cholesterol (TC), and high-density lipoprotein cholesterol 
(HDL-C) levels were measured by using a FUJI Dri-Chem 
3500 system (Fuji Photo Film Co., Osaka, Japan). Concen-
tration of low-density lipoprotein cholesterol (LDL-C), in 
mg per 100 mL, was calculated according to the method 
of Friedewald et al. (18) as follows:
 γ(LDL-C)=γ(TC)–γ(HDL-C)–(γ(TG)/5) /1/
RNA extraction and real-time PCR
Total RNA was obtained from the intestine samples 
by using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s protocol. Reverse tran-
scription was performed by using 1 μg of total RNA with 
fi rst strand cDNA synthesis kit for real-time polymerase 
chain reaction (RT-PCR, Invitrogen) with oligo (dT) 15 as 
a primer (Invitrogen). Aft er cDNA synthesis, real-time 
PCR was performed using a Power SYBR® Green PCR 
Master Mix kit (Applied Biosystems, Foster City, CA, 
USA). Quantitative analysis was carried out using Step-
One plus soft ware v. 2.0 (Applied Biosystems). Results 
were normalized to a validated control gene, β-actin, 
using the ΔΔCt method (19). Using primers to interrogate 
proglucagon and PYY, RT-PCR was performed by a meth-
od reported previously (20). The following primers were 
used for GLP-1 and PYY: proglucagon (NM-012707.2): 
forward primer: 5’-ATGCGGACGAATACATTTCC-3’, re-
verse primer: 5’-CTCAGGGCGGTAACTTCAAA-3’; PYY 
(NM_001034080.1): forward primer: 5’-CAGCGGTATG G-
GAAAAGAGA-3’, reverse primer: 5’-CATGCAAGTG-
AAGTCGGTGT-3’; β-actin (NM-031144.3): forward pri-
mer: 5’-GCTACAGCTTCACCACCACA-3’, reverse primer: 
5’-TGCCGATAGTGATGACCTGA-3’.
Statistical analysis
All statistical analyses were performed using the Sta-
tistical Package for Social Sciences, v. 12.0 (SPSS Inc., Chi-
cago, IL, USA). The statistical signifi cance of diﬀ erences 
was determined using one-way ANOVA at a signifi cance 
level of p<0.05. All data were signifi cant at 95 % level and 
reported as the mean value±standard deviation (S.D.).
Results and Discussion 
GOS content before and after enzymatic hydrolysis and 
fermentation
Table 1 summarizes the content of saccharides during 
diﬀ erent stages of GOS preparation, i.e. the enzymatic hy-
drolysis by β-galactosidase and fermentation by S. cerevi-
siae. Aft er treatment by β-galactosidase, GOS content in-
creased from 0 to 51.0 g per 100 g, and lactose mass 
fractions decreased from 99.2 to 21.3 g per 100 g (Table 1). 
Monosaccharide (glucose and galactose) mass fractions 
also increased from 0.8 to 27.7 g per 100 g aft er the enzy-
matic reaction; however, these monosaccharides were 
completely removed by fermentation with S. cerevisiae, 
whereas lactose levels were slightly increased. In order to 
increase the purity of GOS, fermentation process was uti-
lized. Aft er fermentation, glucose and galactose mass 
fractions decreased from 27.7 to 0.0 g per 100 g (Fig. 1 and 
Table 1). The purity of the GOS preparation increased 









Raw material   0.8±0.1 99.2±2.6 0.0
Aft er enzyme 
reaction 27.7±1.8 21.3±1.0 51.0±3.3
Aft er fermentation 
with S. cerevisiae L1 0.0 26.4±1.3 73.6±2.1
Values are expressed as mean±standard deviation
Fig. 1. Carbohydrate profi le: a) before and b) aft er the fermenta-
tion with Saccharomyces cerevisiae L1
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from 51.0 to 73.6 g per 100 g aft er fermentation with S. 
cerevisiae (Table 1), verifying that HP-GOS were success-
fully produced using the two-step enzymatic hydrolysis 
and fermentation by yeast.
For the production of HP-GOS, selective fermenta-
tion for a given microorganism was characterized. During 
the fermentation, ethanol may be produced depending on 
the used microorganism, which at toxic volume fractions 
may compromise the activity of the microorganism. S. 
cerevisiae was used to increase the purity of the mixture of 
GOS obtained by enzymatic hydrolysis with β-ga lac to-
sidase from Bacillus circulans, with complete removal of 
the monosaccharides (21). The same approach was adopt-
ed for the production of GOS mixture from B. bifi dum bio-
mass (9). In a previous research, Kluyveromyces marxianus 
improved the purity of a GOS mixture produced by 
β-galactosidase from B. circulans from 38 to 97 % by selec-
tive fermentation of mono- and disaccharides (including 
lactose) (6). With a combined use of S. cerevisiae and K. lac-
tis the purity of a GOS mixture produced by β-galac to-
sidase from Penicillium expansum increased from 29 to 98 
% (8). In this work, HP-GOS were produced by fermenta-
tion with S. cerevisiae (Table 1 and Fig. 1), which increased 
the GOS content from 51.0 to 73.6 g per 100 g aft er fer-
mentation with S. cerevisiae.
Utilization of GOS by intestinal bacteria in vitro
HP-GOS comprise substances with structural diﬀ er-
ences and have considerably greater prebiotic potential 
compared to a commercially available GOS mixture. Fig. 
2 shows the growth of intestinal bacteria in a medium 
containing various commercial GOS. In order to confi rm 
that the growth was dependent on GOS utilization, 
strains were also inoculated into PYF basal medium con-
taining 1 % HP-GOS, Y-GOS, C-GOS or Q-GOS as the car-
bohydrate source. During the early stages of growth (af-
ter 12 h), all strains exhibited a similar growth rate 
without signifi cant diﬀ erences. All strains (L. acidophilus, 
L. casei, B. longum and B. bifi dum) in a medium containing 
HP-GOS had a higher cell growth rate than the strains 
grown in the media containing commercial GOS aft er 12 
h of culture. These results suggest that HP-GOS serve as a 
good substrate and carbon source for supporting the 
growth of probiotic bacteria.
Growth curves for the given strains grown anaerobi-
cally in the medium without GOS or with 0.5, 1, 2 or 4 % 
(by mass) GOS are shown in Fig. 3. L. acidophilus and L. 
casei were able to grow at all the tested GOS mass frac-
tions, both reaching a maximum A600 nm of 1.15 aft er 36 h of 
growth. Cell growth was increased with an increase in 
HP-GOS mass fraction. Growth of B. bifi dum and B. long-
um increased rapidly until 12 h and then continued in-
creasing slowly. Therefore, HP-GOS mass fractions above 
1 % were found to be acceptable for the growth of probi-
otic bacteria.
Structural diﬀ erences of GOS vary notably depend-
ing on the conditions and source of enzymes used for 
their synthesis (HP-GOS and Y-GOS were produced from 
4’- or 6’-galactosyl-lactose, and C-GOS and Q-GOS from 
4’-galactosyl-lactose) (4), which aﬀ ects the fermentation 
process as well as their prebiotic properties. Studies of 
t(cultivation)/h
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Fig. 2. Growth of: a) L. acidophilus, b) L. casei, c) B. bifi dum and d) B. longum in modifi ed PYF broth containing 1 % (by mass) of various 
commercial galactooligosaccharides (GOS). Bars represent the standard error of triplicate measurements. Diﬀ erent lett ers indicate 
signifi cant diﬀ erences at p<0.05
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GOS utilization by bacteria have shown that diﬀ erent 
strains vary in their ability to ferment GOS, with individ-
ual strains exhibiting specifi c substrate preferences (22, 
23).
We additionally analyzed the utilization of GOS by 
various probiotic bacteria (Fig. 2). L. acidophilus, L. casei, B. 
bifi dum and B. longum had a higher cell growth rate when 
utilizing HP-GOS in comparison with commercial GOS 
(Fig. 2), suggesting that 4’- or 6’-galactosyl-lactose may be 
a more suitable substrate for these strains. The utilization 
of GOS by a number of probiotic bacteria has been exten-
sively analyzed (24,25). It has been shown that 4’-galacto-
syl-lactose is selectively utilized by all the Bifi dobacterium 
strains tested, compared with lactulose and raﬃ  nose, 
whose specifi city is less noticeable. Other studies have 
also shown that some strains of Lactobacillus, Bacteroides 
and Clostridium ferment GOS, and that transgalactosylat-
ed disaccharides may even be bett er substrates for these 
bacteria (26). Some bacterial species can ferment both 4’- 
and 6’-galactosyl-lactose, although there are some diﬀ er-
ences and the growth of bacteria is dose-dependent.
As shown in Fig. 3, B. bifi dum and B. longum utilized 
HP-GOS more rapidly than L. acidophilus and L. casei. It is 
considered that the utilization of non-digestible oligosac-
charides (NDOs) by bifi dobacteria is mediated by the hy-
drolyzing enzymes produced by these strains. Many Bifi -
dobacterium strains produce glycolytic enzymes that 
hydrolyze a wide range of monosaccharides and various 
glycosidic bonds, while the activities of the enzymes from 
other enteric bacteria such as Lactobacillus, Escherichia coli 
and Streptococcus are less varied and are weaker than 
those from Bifi dobacterium (27).
Changes in body mass, organ mass and serum parameters
Changes in body mass and organ mass of the rats in 
control, HP-GOS, HP-GOS+BB and BB groups are shown 
in Table 2. No signifi cant diﬀ erences in body mass were 
found among the three groups. The changes in the masses 
of the liver and other internal organs of the rats aft er a 
5-week administration of each diet are shown in Table 3. 
























































































Fig. 3. Growth of: a) L. acidophilus, b) L. casei, c) B. bifi dum and d) B. longum in modifi ed PYF broth containing various mass fractions 
of high-purity galactooligosaccharides (HP-GOS). Bars represent the standard error of triplicate measurements
Table 2. Changes in body mass of rat aft er treatment with galac-
tooligosaccharides and/or bifi dobacteria
Group
t/week
1 2 3 4 5
m/g
Control 44.7±1.0 90.8±2.7 147.7±5.2 201.4±7.4 230.5±6.1
HP-GOS 42.5±2.0 82.0±2.2 129.5±4.7 176.5±6.6 210.6±7.0
BB 43.5±1.5 88.3±3.3 139.6±3.1 193.0±7.9 219.0±8.2
HP-GOS+BB 45.2±1.9 90.3±3.3 147.0±5.1 196.6±5.8 224.3±6.0
Values are expressed as mean±standard deviation. Control=oral 
administration of saline, HP-GOS=oral administration of 
high-purity galactooligosaccharides, BB=oral administration of 
bifi dobacteria, HP-GOS+BB=oral administration of HP-GOS and 
bifi dobacteria
Table 3. Changes of organ mass of rat aft er treatment with ga-
lactooligosaccharides and/or bifi dobacteria
Organ
w/(g/100 g)
Control HP-GOS BB HP-GOS+BB
Liver 9.0±0.1 8.4±0.5 8.7±0.4 8.9±0.2
Kidney 2.3±0.1 2.1±0.1 2.3±0.1 2.3±0.2
Spleen 0.7±0.0 0.6±0.0 0.8±0.0 0.7±0.0
Values are expressed as mean±standard deviation. Control=oral 
administration of saline, HP-GOS=oral administration of 
high-purity galactooligosaccharides, BB=oral administration of 
bifi dobacteria, HP-GOS+BB=oral administration of HP-GOS and 
bifi dobacteria
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No diﬀ erences were observed in the masses of the liver, 
spleen and kidney in relation to the body mass in all 
groups.
Serum glucose, protein, aspartate aminotransferase 
(AST), alanine aminotransferase (ALT) and lipid profi les 
are shown in Table 4. Groups administered HP-GOS+BB 
had signifi cantly diﬀ erent AST and ALT levels compared 
with the control group or the group administered HP- 
-GOS, respectively (p<0.05). However, the ALT and AST 
levels of the group administered HP-GOS+BB were in the 
normal range for SD rats (17.30–19.77 and 74.4–80.4 U/L, 
respectively) (28). There were no signifi cant diﬀ erences in 
the lipid profi les (total cholesterol, HDL cholesterol and 
triacyglycerol) among the groups.
Enumeration of bifi dobacteria in rat faeces
Fig. 4 shows the total bifi dobacteria counts in rat fae-
ces, expressed in log CFU per g of faeces, during four pe-
riods of the study. The groups that were orally adminis-
tered HP-GOS and bifi dobacteria had signifi cantly 
(p<0.05) higher counts during all four periods, while the 
group receiving HP-GOS had higher counts in the 2nd 
and 4th period only in comparison with the control and 
BB group. In the 2nd and 3rd periods, the same trend was 
observed in groups administered HP-GOS and HP- 
-GOS+BB. During the entire period, oral administration of 
HP-GOS+BB resulted in higher bifi dobacteria counts than 
the oral administration of control or single administration 
of bifi dobacteria. There was no signifi cant diﬀ erence in 
bifi dobacteria counts between the HP-GOS+BB group and 
the HP-GOS group in the 2nd and 4th periods.
Bifi dobacteria in rat faecal samples were counted in 
the HP-GOS groups with or without bifi dobacteria. Our 
results indicated a positive eﬀ ect in the synbiotic group 
(HP-GOS+BB) during the test periods. It is known that 
most bifi dobacteria strains of human intestinal origin can 
readily use galactooligosaccharides; however, only a few 
strains from other genera, such as lactobacilli, possess this 
ability (24,26). As far as the eﬀ ects of probiotic consump-
tion on the bifi dobacterial population are concerned, sim-
ilar results have been observed in children and adults. 
Benno and Mitsuoka (29) reported an increase in the 
counts of bifi dobacteria as well as a remarkable decrease 
in the counts of clostridia in adult human subjects con-
suming a daily dose of B. longum.
Expression of genes encoding GLP-1 and PYY in ileum
There was an approx. 1.6-fold increase in PYY mRNA 
levels in the ileum of rats administered GOS+BB (Fig. 5), 
which was signifi cantly higher than in the other groups 
(p<0.05). Similarly, GLP-1 mRNA levels in the ileum of 
rats administered GOS+BB and only bifi dobacteria were 
1.5- and 1.6-fold higher, respectively, than in rats fed nor-
mal diet. There was a signifi cant upregulation of GLP-1 
and PYY mRNA with GOS+BB intake.
Endocrine cells in the intestinal mucosa secrete pep-
tides involved in the regulation of food intake and/or 
pancreatic function; the latt er are known as incretins 
(30,31). Endocrine L cells are distributed throughout the 
intestinal tract, and are predominantly present in the 
caeco-colon, where fermentation of inulin-type fructans 
occurs (32). GLP-1 and PYY, which are released from in-
testinal L cells, modulate appetite and thus reduce food 
intake (33). The ability of prebiotic fi bre to increase the 
proglucagon mRNA levels and GLP-1 secretion is well 
supported (34,35). Increased proglucagon expression typ-
ically takes place when caecal mass is increased due to 
the markedly increased bacterial fermentation that occurs 
with the consumption of prebiotics (34,35). It is interest-
ing to note that the fi bre-containing prebiotic diet appears 
to have acute and lasting eﬀ ects on the ability of L cells to 
produce and secrete GLP-1 and PYY. In the current study, 





















































Fig. 4. Number of total bifi dobacteria in rat faeces, expressed as 
mean values of log colony-forming units (CFU) per g of wet 
faeces, N=6. Bars represent the standard error of triplicate mea-
surements. Diﬀ erent lett ers indicate signifi cant diﬀ erences at 
p<0.05. HP-GOS=high-purity galactooligosaccharides, BB=bifi -
do bacteria
Table 4. Serum levels of glucose, total protein, AST, ALT, and lipid profi les of rats
Group
γ(glucose) γ(total protein) AST ALT γ(TC) γ(HDL-C) γ(LDL-C) γ(TG)
mg/dL g/dL U/L U/L mg/dL mg/dL mg/dL mg/dL
Control 110.7±2.6 18.62±0.07 74.4±2.2b  18.6±0.6ab 79.2±2.5 52.7±2.8 11.4±3.0 75.3±3.0
HP-GOS 111.5±5.4 19.77±0.09  79.6±0.8ab 19.8±0.7a 83.8±2.5 56.2±2.3 14.6±1.6 77.7±1.7
BB 104.0±1.4 18.42±0.09  75.2±1.6ab  18.4±0.9ab 78.7±1.6 54.6±2.0 10.5±3.9 73.5±1.7
HP-GOS+BB 114.5±4.4 17.30±0.08 80.4±1.7a 17.3±0.6b 85.3±0.6 56.0±1.5 16.0±0.8 77.8±1.3
Values are expressed as mean±standard deviation, N=8. Mean values with diﬀ erent lett ers in superscript within the column are 
signifi cantly diﬀ erent at p<0.05 by Duncan’s multiple range tests. AST=aspartate aminotransferase, ALT=alanine aminotransferase, 
TC=total cholesterol, HDL-C=high-density lipoprotein cholesterol, LDL-C=low-density lipoprotein cholesterol, TG=triglyceride. 
Control=oral administration of saline, HP-GOS=oral administration of high-purity galactooligosaccharides, BB=oral administration of 
bifi dobacteria, HP-GOS+BB=oral administration of HP-GOS and bifi dobacteria
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at the end of a 5-week period, when GOS as prebiotics 
were administered as part of the diet; however, we addi-
tionally found higher expression of genes encoding GLP- 
-1 and PYY in the HP-GOS group with or without B. bifi -
dum at the end of the period in which the high fat-based 
diet was administered (Fig. 5).
It is acknowledged that an optimum balance in mi-
crobial populations in the digestive tract is associated 
with good nutrition and health, and that this may be 
achieved by the consumption of probiotics. In particular, 
HP-GOS exhibit a greater prebiotic activity than other 
commercial GOS.
Conclusion
High-purity galactooligosaccharides (HP-GOS) were 
successfully produced using a two-step process, enzy-
matic hydrolysis and fermentation by yeast. They were 
found to serve as a good substrate and carbon source for 
supporting the growth of enteric bacteria, compared with 
other commercial GOS. The benefi cial eﬀ ect of regular in-
take of HP-GOS is att ributed to the intestinal survival of 
probiotic Lactobacillus and Bifi dobacterium strains. The 
health benefi ts associated with the consumption of HP- 
-GOS in humans include improvement of intestinal tract 
health, increase in the expression of genes encoding GLP-
-1 and PYY, decrease in the risk of certain cancers, blood 
pressure control, and reduction of serum cholesterol lev-
els. On the basis of our fi ndings, we propose that the pre-
biotic properties of HP-GOS are valuable in the produc-
tion of potential health-enhancing foods and supplements, 
and that HP-GOS may be used as a functional food ingre-
dient for human consumption.
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